Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Am J Obstet Gynecol. 2013 May 6;209(3):244.e1–244.e9. doi: 10.1016/j.ajog.2013.05.008

Table 4. Summary of indications for the Extended Evaluation (ExE, n (%))*.

Offered ExE
(n=83)
Completed ExE
(n=22)
Indication for ExE
Post Void Residual >250cc twice in one day 3 (3) 2 (9)
Side effects too bothersome 39 (43) 9 (40)
Symptoms did not improve 32 (35) 14 (64)
Urinary Tract Infection 1 (1) 1 (5)
Other** 16 (19) 0 (0)
No reason*** 1 (1) 1 (5)
*

May sum to greater than 100% as participants could have more than one reason for ExE

**

Other reasons included: physician recommendation, other health reason, participant circumstances, “wait and see” what happens upon medication discontinuation, and other

***

One woman had an ExE with her private physician without having a study indication for ExE